Latest News & Features
Regulation & Industry
Pitching for business has always been a partner’s game. One in-house team decided junior lawyers needed a seat at the table, building a programme to close an “industry-wide gap” in vital experience. Marisa Woutersen spoke with organisers Regeneron and associates from A&O Shearman, Hoyng Rokh Monegier, and Bristows, who stepped up to ‘sell’ their firms. 14 September 2026
Regulation & Industry
For biotech companies, promising science is no longer enough to attract a pharma buyer. Lawyers from Morrison Foerster, Polsinelli, Morgan Lewis and Dechert explain what makes an acquisition target truly deal-ready. Marisa Woutersen explores what companies should get right before a potential acquirer comes knocking. 11 September 2026
Regulation & Industry
UPC judges and practitioners from firms including Freshfields, Kather Augenstein, EIP, Simmons & Simmons and Brinkhof converged at CIPA’s annual conference to offer candid views on the court’s biggest pressure points, from overloaded German divisions to harmonisation and cross-court influence. 10 September 2026
Careers
The senior lawyer previously led Johnson & Johnson’s global pharmaceutical patent team, advising on patent portfolios, R&D, licensing, M&A and litigation. 10 September 2026
Pharma
Four patents stood firm in a Johnson & Johnson unit’s fight with Sandoz, leaving the generics maker facing a lengthy wait before its esketamine nasal spray can reach the US market. 10 September 2026
MedTech
The UPC has handed the medical device company a significant win over continuous glucose monitoring tech, granting a broad provisional injunction after finding that SiBio’s rival system was likely to infringe its European patent. 9 September 2026
Careers
With technical specialisms including nucleic acid technologies, biological therapeutics and vaccines, and diagnostics and biological assays, the new hire adds a life sciences patent specialism to the firm’s growing IP practice. 8 September 2026
Pharma
A single phrase in a patent has proved decisive in Biofer’s infringement fight with Vifor, with the Federal Circuit exposing the risks of small claim-drafting choices for life sciences companies. 7 September 2026
Regulation & Industry
Clarity from the Enlarged Board of Appeal for when patent descriptions must be amended to reflect changes to the claims has finally arrived. LSIPR outlines G 1/25, the debate that led to the referral and the EPC provisions at the heart of the ruling. 4 September 2026
Regulation & Industry
Lawmakers support a bill that would place guardrails on lawyers’ use of generative AI for court filings, in a bid to clamp down on AI ‘hallucinations’ and inaccuracies. 4 September 2026